The World Health Organization (WHO) officially validated the CONVIDECIA COVID-19 vaccine (adenovirus type-5-vectored vaccine) developed by Chinese company CanSino Biologics for emergency use on May 19, according to the information provided to the National Medical Products Administration (NMPA) by the WHO and the information released on the WHO's official website. The CONVIDECIA COVID-19 vaccine is the third Chinese vaccine listed by the WHO for emergency use after the inactivated COVID-19 vaccine developed by Sinopharm-affiliated Beijing Institute of Biological Products and the inactivated COVID-19 vaccine developed by Sinovac.

The NMPA has long maintained a good consultative relationship with the WHO, and has cooperated with the WHO on issues including regulation of COVID-19 vaccines.